Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock is trading lower on Thursday; however, there is no news to justify the movement. The stock could possibly be down on profit-taking after the stock closed nearly 15% higher on Wednesday.On Tuesday, the company shared positive results from its Phase 1b clinical trial for its lead candidate, PH-762.PH-762 Shows 85% Pathological Response RatePhio Pharmaceuticals’ lead clinical program is PH-762 (often referred to in the context of their INTASYL platform), which is ...